Skip to main content
IDWeek 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

241. PK/PD Studies: Saturday, 12:15 - 1:30 p.m.

Poster Session: PK/PD Studies

(2553) Safety, tolerability and pharmacokinetics of HS-10366 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase 1 trial.

Saturday, October 14, 2023
12:15 PM – 1:30 PM US ET
Location: Virtual

    Presenting Author(s)

  • Xiaoyan Liu, PhD (she/her/hers)

    107 Wenhua Xi Road, Jinan, Shandong, 250012, China
    Phase 1 Clinical Trial Center, Qilu Hospital of Shandong University; NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drugs
    Jinan, Shandong, China

    • Co-Author(s)

  • RZ

    Rui Zhang, PhD

    Phase 1 Clinical Trial Center, Qilu Hospital of Shandong University; NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drugs
    Jinan, Shandong, China

  • RL

    Rong Li, PhD

    Phase 1 Clinical Trial Center, Qilu Hospital of Shandong University; NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drugs
    Jinan, Shandong, China

  • QW

    Qiong Wu, MD

    Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Shanghai, Shanghai, China

  • CP

    Chao Pan, MD

    Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Shanghai, Shanghai, China

  • XY

    Xiangqing Yu, PhD

    Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Shanghai, Shanghai, China

  • WJ

    Wen Jia, MD

    Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Shanghai, Shanghai, China

  • PX

    Peng Xia, MD

    Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Shanghai, Shanghai, China

  • YL

    Yuhui Liu, PhD

    Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Shanghai, Shanghai, China

  • BW

    Benjie Wang, PhD

    Phase 1 Clinical Trial Center, Qilu Hospital of Shandong University; NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drugs
    Jinan, Shandong, China

  • SY

    Shuwen Yu, PhD

    Phase 1 Clinical Trial Center, Qilu Hospital of Shandong University; NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drugs
    Jinan, Shandong, China